Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical
company dedicated to the discovery, development and
commercialization of novel therapies for the treatment of cancer
and related conditions, today announced that four abstracts have
been accepted for presentation at the 2019 American Society of
Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June
4, 2019 at the McCormick Place Convention Center in Chicago,
Illinois.
“We are very pleased with the abstracts that have been accepted
for presentation at ASCO this year,” said Dr. Johnson Lau, Chairman
and Chief Executive Officer of Athenex. “We look forward to sharing
additional information on our lead, pivotal stage Oraxol (Oral
paclitaxel and HM30181A) program as well as preliminary results
from our Oratecan (Oral irinotecan and HM30181A) Phase I study and
preclinical proof of concept data for our new arginine deprivation
therapy platform, Pegtomarginase. We believe these will demonstrate
the broad applicability of the Orascovery technology for a wide
range of commonly used chemotherapy agents and the depth of our
oncology-focused pipeline.”
Presentation details:
Title: (Abstract TPS1116) KX-ORAX-001: An open
label, randomized, multicenter, Phase III registrational study to
determine the safety, tolerability, and tumor response of Oraxol
(HM30181A + oral paclitaxel) and its comparability to IV paclitaxel
in patients with metastatic breast cancer (MBC).Poster
Session: Breast Cancer—MetastaticSession Date,
Time, Location: Sunday June 2, 2019, 8:00 AM-11:00 AM
Central Daylight Time, Hall A
Title: (Abstract 1084) Oral paclitaxel in the
treatment of metastatic breast cancer (MBC) patients.Poster
Session: Breast Cancer—MetastaticSession Date,
Time, Location: Sunday June 2, 2019, 8:00 AM-11:00 AM
Central Daylight Time, Hall A
Title: (Abstract 3032) A Phase 1 study of the
oral administration of irinotecan in combination with the potent
P-glycoprotein (P-gp) inhibitor HM30181A.Poster
Session: Developmental Therapeutics and Tumor Biology
(Nonimmuno)Session Date, Time, Location: Saturday
June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
Title: (Abstract 3090) Design, engineering, and
characterization of a novel long-acting (Pegylated) single isomer
human arginase for arginine depriving anti-cancer
treatment.Poster Session: Developmental
Therapeutics and Tumor Biology (Nonimmuno)Session Date,
Time, Location: Saturday June 1, 2019, 8:00 AM-11:00 AM
Central Daylight Time, Hall A
The abstract titles are currently available on the ASCO iPlanner
website, with the full abstracts scheduled to be published on May
15, 2019.
Athenex has received approval of the International
Nonproprietary Name (INN) “encequidar” for its novel P-gp pump
inhibitor molecule, HM30181A. The Company may use the nomenclature
“encequidar” in future communications.
The Orascovery platform was initially developed by Hanmi
Pharmaceuticals and licensed exclusively to Athenex for all major
worldwide territories except Korea, which is retained by Hanmi.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; and multiple locations
in Chongqing, China. For more information, please
visit www.athenex.com.
Forward-Looking StatementExcept for historical
information, all of the statements, expectations, and assumptions
contained in this press release are forward-looking statements.
These forward-looking statements are typically identified by terms
such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “foresee,” “guidance,” “intend,” “likely,” “may,” “plan,”
“potential,” “predict,” “probable,” “project,” “seek,” “should,”
“will,” and similar expressions. Actual results might differ
materially from those explicit or implicit in the forward-looking
statements. Important factors that could cause actual results to
differ materially include: the development stage of our primary
clinical candidates and related risks involved in drug development,
clinical trials, regulation, manufacturing and commercialization;
our reliance on third parties for success in certain areas of
Athenex’s business; our history of operating losses and need to
raise additional capital to continue as a going concern;
competition; intellectual property risks; risks relating to doing
business in China; and the other risk factors set forth from time
to time in our SEC filings, copies of which are available for free
in the Investor Relations section of our website at
http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon
request from our Investor Relations Department. All information
provided in this release is as of the date hereof and we assume no
obligation and do not intend to update these forward-looking
statements, except as required by law.
CONTACTS
Investor Relations:
Tim McCarthy Managing Director, LifeSci Advisors, LLC Tel:
+1 716-427-2952 Direct: +1 212-915-2564
Athenex, Inc.:
Randoll Sze Chief Financial Officer
Email: randollsze@athenex.com
Jacqueline Li Corporate Development and Investor Relations
Email: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024